ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.2817C>T (p.Thr939=) (rs367921107)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000165865 SCV000216614 likely benign Hereditary cancer-predisposing syndrome 2014-09-08 criteria provided, single submitter clinical testing
Color RCV000165865 SCV000683503 benign Hereditary cancer-predisposing syndrome 2016-07-04 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000430864 SCV000591827 likely benign not specified 2014-08-20 criteria provided, single submitter clinical testing
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000494816 SCV000578881 likely benign Breast-ovarian cancer, familial 2 2017-06-29 reviewed by expert panel curation Synonymous substitution variant, with low bioinformatic likelihood to result in a splicing aberration (Splicing prior probability 0.02; http://priors.hci.utah.edu/PRIORS/).
GeneDx RCV000430864 SCV000512351 benign not specified 2015-07-06 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Integrated Genetics/Laboratory Corporation of America RCV000430864 SCV000918834 likely benign not specified 2017-09-19 criteria provided, single submitter clinical testing Variant summary: The BRCA2 c.2817C>T (p.Thr939Thr) variant involves the alteration of a non-conserved nucleotide, resulting in a synonymous change. Mutation taster predicts a benign outcome for this variant. 3/5 splice prediction tools predict no significant impact on normal splicing. ESE finder predicts that this variant may affect ESE site of SF2/ASF and SRp40. However, these predictions have yet to be confirmed by functional studies. This variant was found in 13/245704 control chromosomes, predominantly observed in the Latino subpopulation at a frequency of 0.000269 (9/33504). This frequency is only about 2.7 fold lower than the estimated maximal expected allele frequency of a pathogenic BRCA2 variant (0.0007503), suggesting this is possibly a rare benign polymorphism found primarily in the populations of Latino origin. The variant has been observed in a breast cancer patient along with a likely pathogenic BRCA2 variant (c.8488-1G>A; Santos_2014) suggesting this variant is not the cause of breast cancer in this patient. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as benign/likely benign. Taken together, this variant is classified as Likely Benign, until additional information is available.
Invitae RCV000195768 SCV000253006 likely benign Hereditary breast and ovarian cancer syndrome 2017-10-03 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000759593 SCV000889012 benign not provided 2017-11-15 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.